Adjuvant melanoma therapy with new drugs : should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

Grob, Jean Jacques; Garbe, Claus; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Schadendorf, Dirk

dc.contributor.author	Garbe, Claus
dc.date.accessioned	2019-07-08T07:48:26Z
dc.date.available	2019-07-08T07:48:26Z
dc.date.issued	2018
dc.identifier.issn	1474-5488
dc.identifier.uri	http://hdl.handle.net/10900/90120
dc.language.iso	en	de_DE
dc.publisher	Elsevier Science Inc	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/S1470-2045(18)30596-5	de_DE
dc.subject.ddc	610	de_DE
dc.title	Adjuvant melanoma therapy with new drugs : should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190321153956_00281
utue.publikation.seiten	E720-E725	de_DE
utue.personen.roh	Grob, Jean Jacques
utue.personen.roh	Garbe, Claus
utue.personen.roh	Ascierto, Paolo
utue.personen.roh	Larkin, James
utue.personen.roh	Dummer, Reinhard
utue.personen.roh	Schadendorf, Dirk
dcterms.isPartOf.ZSTitelID	Lancet Oncology	de_DE
dcterms.isPartOf.ZS-Issue	12	de_DE
dcterms.isPartOf.ZS-Volume	19	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE